Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,943,751 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,943,751 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,942,323 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,942,323 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,966,320 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,966,320 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,976,036 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,976,036 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,958,949 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,958,949 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 45,010 | $98.64 | $4,439,786.40 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,957,650 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.05 to $99.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 17,105 | $97.61 | $1,669,619.05 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,002,660 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.05 to $98.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,309 | $96.48 | $512,212.32 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,019,765 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.02 to $97.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 38,109 | $4.18 | $159,295.62 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,025,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 25,255 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-006925 · wf-form4_155804300443992.xml · derivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,827 Underlying: COMMON STOCK · 25,255 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price of $4.17 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. F5 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. F6 · derivative.expiration_date: The expiration date of July 13, 2027 reported in the Reporting Person's Form 3 filed on October 3, 2018 was in error. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 54,128 | $72.47 | $3,922,656.16 |
DisclosureSEC source: 0001628280-19-006925 · wf-form4_155804300443992.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,986,965 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.28 to $72.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:43 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,532 | $72.05 | $1,767,530.60 |
DisclosureSEC source: 0001628280-19-006925 · wf-form4_155804300443992.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,041,093 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18per share. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.28 to $72.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 14, 2019 Filed May 16, 2019 21:43 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 25,255 | $4.18 | $105,565.90 |
DisclosureSEC source: 0001628280-19-006925 · wf-form4_155804300443992.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,065,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,158 | $64.95 | $399,962.10 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.58 to $65.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,749 | $64.15 | $497,098.35 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 6,158 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.58 to $64.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,750 | $65.08 | $244,050.00 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.88 to $65.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,157 | $64.29 | $652,993.53 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 3,750 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.87 to $64.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,529 | $65.11 | $294,883.19 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 0 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.79 to $65.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,378 | $64.21 | $602,161.38 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 4,529 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $67.20 | $6,720.00 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 13,907 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,068 | $66.50 | $337,022.00 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 14,007 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.20 to $67.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,705 | $65.53 | $1,618,918.65 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 19,075 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.20 to $66.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,999 | $66.52 | $332,533.48 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 13,907 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.21 to $67.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,874 | $65.54 | $1,630,241.96 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 18,906 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.19 to $66.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,602 | $66.47 | $372,364.94 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 13,907 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.20 to $67.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 30, 2019 Filed May 2, 2019 21:20 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,271 | $65.52 | $1,590,235.92 |
DisclosureSEC source: 0001628280-19-005705 · wf-form4_155683202270643.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 19,509 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.20 to $66.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $68.72 | $6,872.00 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 16 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 43,780 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,823 | $68.40 | $124,693.20 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 43,880 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F16 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.89 to $68.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,708 | $67.18 | $181,923.44 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 45,703 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F15 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.89 to $67.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,425 | $66.24 | $226,872.00 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 48,411 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.88 to $66.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,977 | $65.25 | $520,499.25 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 51,836 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.88 to $65.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,967 | $64.27 | $897,659.09 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 59,813 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.86 to $64.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,415 | $68.32 | $96,672.80 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 43,780 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.90 to $68.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,040 | $67.19 | $204,257.60 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 45,195 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.80 to $67.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,978 | $66.03 | $328,697.34 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 48,235 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.80 to $66.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 9,022 | $65.14 | $587,693.08 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 53,213 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,545 | $64.20 | $741,189.00 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 62,235 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 1,561 | $68.35 | $106,694.35 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 43,780 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.82 to $68.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,597 | $67.24 | $174,622.28 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 45,341 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.80 to $67.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 5,437 | $66.10 | $359,385.70 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 47,938 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.80 to $66.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 7,656 | $65.18 | $499,018.08 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 53,375 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.80 to $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 23:49 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,749 | $64.23 | $818,868.27 |
DisclosureSEC source: 0001628280-19-004663 · wf-form4_155614977424576.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 61,031 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.80 to $64.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionSERIES A PREFERRED STOCK · Derivative | 87,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · derivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: COMMON STOCK · 87,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.exercise_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F1 · derivative.expiration_date: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 73,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Genevieve Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 73,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 664,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Eltoukhy Investments, L.P. Disclosed balance after: 664,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 73,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Camille Eltoukhy Irrevocable Trust Disclosed balance after: 73,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 73,780 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Isabella Eltoukhy 2018 Irrevocable Trust Disclosed balance after: 73,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 4,040,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,040,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
| October 09, 2018 Filed Oct 11, 2018 20:28 UTC | Guardant Health, Inc. GH · Entity 3238 | ConversionCOMMON STOCK | 87,753 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-18-012481 · wf-form4_153928966379408.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Helmy A. Eltoukhy Revocable Trust Disclosed balance after: 119,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.